Collaborative Drug Discovery Announces New Grant Supplement for Tuberculosis (TB) Drug Accelerator
The $2,517,214 supplemental grant from the Bill & Melinda Gates Foundation provides CDD Vault for secure data sharing and collaborative analytics services and support across the Tuberculosis (TB) Drug Accelerator (TBDA).
Burlingame, California — November 8, 2022 — Collaborative Drug Discovery has received a $2,517,214 supplemental grant from the Bill & Melinda Gates Foundation to provide CDD Vault for secure data sharing and collaborative analytics services and support across the Tuberculosis (TB) Drug Accelerator (TBDA).
The TBDA is a public private collaboration between multiple international big pharmaceutical companies, leading academic researchers, and non-profit organizations. Although by default structures and bioactivity are private, when approved by all organizations involved, lead series are selectively shared (“disclosed”) with the broader group for greater efficiency.
The TBDA “aims to identify new drugs that work differently than existing drugs to kill bacteria. The program has developed new tools for drug discovery, and by bringing together academic and industry partners in a unique collaboration, it facilitates the sharing of best practices, methods, and data.” It is part of the broader effort to develop a treatment regimen that is safer, shorter, simpler, and affordable. More information can be found online at:
The TB bacillus infects more than a quarter of the world’s population and the disease kills over 1.5 million people every year. The CDD Vault TB database (TBDB) integrates the efforts of academic, non-profit, and corporate laboratories distributed across the globe to help accelerate the discovery of new therapies against this deadly disease.
The CDD team has been dedicated to supporting global neglected disease research for over a decade. CDD CEO Dr. Barry Bunin commented, “As Collaborative Drug Discovery, Inc. becomes a larger and more profitable organization, we remain as dedicated to our roots as the day we were founded over 18 years ago and committed to supporting global neglected, humanitarian, as well as mainstream commercial drug discovery with CDD Vault.”
About TB Drug Accelerator (TBDA)
Launched in August 2012, TB Drug Accelerator (TBDA) is a ground-breaking partnership between pharmaceutical companies and research organizations with support from the Bill & Melinda Gates Foundation. Aided by an initial investment of nearly U.S. $20 million (approx. €16.5 million) from the Gates Foundation, the TBDA aims to develop new pre-clinical drug candidates with treatment-shortening potential and provide proof-of-concept for a one-month three-drug regime, by 2022. The long-term goal of the TBDA is to create a TB drug regimen that cures patients in only one month, rather than the 6 months now needed for treatment. Learn more at https://globalhealthprogress.org/collaboration/tb-drug-accelerator-program/
About Collaborative Drug Discovery, Inc.
CDD’s (www.collaborativedrug.com) flagship product, “CDD Vault®”, is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.
A complete list of more than 60 publications and patents from CDD can be found online on our resources page at https://www.collaborativedrug.com/publications-and-resources/.
Media Contact: Barry Bunin, Ph.D., Collaborative Drug Discovery, [email protected]